Last 12 months
Inside the activity.
0 purchase rows · 34 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 23, 2023 01:55 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 2,891 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006583 · form4.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,891 Underlying: Common Stock · 2,891 shares Expires 2033-02-17 F4 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · derivative · entry 7 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 28,125 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · derivative · entry 6 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:51 UTC |
Flynn Sean C.SVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006580 · form4.xml · derivative · entry 5 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 179,147 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,147 Underlying: Common Stock · 179,147 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC |
Colangelo DominickDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,353 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,353 Underlying: Common Stock · 3,353 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:09 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005118 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $29.30 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:09 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 840 | $29.30 | $24,612.00 |
DisclosureSEC source: 0001127602-23-005118 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,197 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:09 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005118 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:06 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005117 · form4.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $29.30 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:06 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 1,983 | $29.30 | $58,101.90 |
DisclosureSEC source: 0001127602-23-005117 · form4.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,283 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:06 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005117 · form4.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $29.30 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,515 | $29.30 | $102,989.50 |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,736 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:05 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003988 · form4.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $30.60 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:05 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 310 | $30.60 | $9,486.00 |
DisclosureSEC source: 0001127602-23-003988 · form4.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:05 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003988 · form4.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:03 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003986 · form4.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $30.60 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:03 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 988 | $30.60 | $30,232.80 |
DisclosureSEC source: 0001127602-23-003986 · form4.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,766 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:03 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003986 · form4.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $30.60 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,253 | $30.60 | $99,541.80 |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,751 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 6,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:04 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
SaleCommon Stock | 330 | $31.00 | $10,230.00 |
DisclosureSEC source: 0001127602-23-003302 · form4.xml · nonDerivative · entry 1 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 39,938 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,938 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 39,938 | $27.13 | $1,083,597.82 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,066 F2 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 39,938 | $25.80 | $1,030,400.40 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2022 Filed Feb 13, 2023 21:42 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantCommon Stock | 104 | $19.41 | $2,018.64 |
DisclosureSEC source: 0001127602-23-004890 · form5.xml · nonDerivative · entry 4 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,008 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 20:01 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
SaleCommon Stock | 331 | $25.47 | $8,430.57 |
DisclosureSEC source: 0001127602-22-024068 · form4.xml · nonDerivative · entry 1 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:57 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-023522 · form4.xml · derivative · entry 3 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Common Stock · 937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $23.20 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on September 30, 2021. The remaining RSUs will vest in annual installments on September 30, 2023, September 30, 2024, and September 30, 2025, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:57 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 276 | $23.20 | $6,403.20 |
DisclosureSEC source: 0001127602-22-023522 · form4.xml · nonDerivative · entry 2 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:57 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023522 · form4.xml · nonDerivative · entry 1 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on September 30, 2021. The remaining RSUs will vest in annual installments on September 30, 2023, September 30, 2024, and September 30, 2025, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2022 Filed Feb 13, 2023 21:39 UTC |
Flynn Sean C.SVP, General Counsel
|
GrantCommon Stock | 25 | $19.72 | $493.00 |
DisclosureSEC source: 0001127602-23-004886 · form5.xml · nonDerivative · entry 3 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,088 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2022 Filed Feb 13, 2023 21:42 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantCommon Stock | 121 | $19.72 | $2,386.12 |
DisclosureSEC source: 0001127602-23-004890 · form5.xml · nonDerivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,904 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2022 Filed Feb 13, 2023 21:39 UTC |
Flynn Sean C.SVP, General Counsel
|
GrantCommon Stock | 403 | $21.40 | $8,624.20 |
DisclosureSEC source: 0001127602-23-004886 · form5.xml · nonDerivative · entry 2 Flynn Sean C. · CIK 0001801993 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,063 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2022 Filed Feb 13, 2023 21:42 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantCommon Stock | 110 | $21.40 | $2,354.00 |
DisclosureSEC source: 0001127602-23-004890 · form5.xml · nonDerivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,783 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC |
WRIGHT LISADirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-001058 · primary_01.xml · derivative · entry 2 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867 Underlying: Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in equal annual installments over three years, beginning on June 1, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC |
WRIGHT LISADirector
|
Exercise / conversionCommon Stock | 433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-001058 · primary_01.xml · nonDerivative · entry 1 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on June 1, 2021. Read SEC document |
| April 29, 2022 Filed May 2, 2022 20:07 UTC |
GILMAN STEVEN CDirector
|
SaleCommon Stock | 900 | $30.94 | $27,846.00 |
DisclosureSEC source: 0001593968-22-000897 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC |
ZERBE ROBERT L MDDirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $31.99 | $0.00 |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-04-27 F7 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC |
ZERBE ROBERT L MDDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. Vested shares will be delivered to the Reporting Person following termination of service on the Company's Board of Directors. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 28, 2021, the Reporting Person deferred the receipt of 2,600 shares of Common Stock and instead received 2,600 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Company's Non-Employee Directors' Deferred Compensation Program. The units will be payable only in shares of Common Stock after the end of the Reporting Person's service on the Company's Board of Directors. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 28, 2021, the Reporting Person deferred the receipt of 2,600 shares of Common Stock and instead received 2,600 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:22 UTC |
WRIGHT LISADirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $31.99 | $0.00 |
DisclosureSEC source: 0001593968-22-000894 · primary_01.xml · derivative · entry 4 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-04-27 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:22 UTC |
WRIGHT LISADirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000894 · primary_01.xml · derivative · entry 3 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:22 UTC |
WRIGHT LISADirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000894 · primary_01.xml · derivative · entry 2 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,351 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:22 UTC |
WRIGHT LISADirector
|
Exercise / conversionCommon Stock | 2,351 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000894 · primary_01.xml · nonDerivative · entry 1 WRIGHT LISA · CIK 0001865017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on June 1, 2021. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:14 UTC |
Wotton Paul KDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000892 · primary_01.xml · derivative · entry 4 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.